Physician profile
Peter Koh
NPI 1861488843
$3,443.43
in general payments reported to CMS, 2019-2025
17 companies · $576 in 2025
The $576 reported for 2025 was more than what 81% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $626 · 2020: $258 · 2021: $333 · 2022: $343 · 2023: $859 · 2024: $448 · 2025: $576.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,883.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,882.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $587.38 | 2023 | Kxl1b-Ce-Marked Kxlsystem, Kxl System (Not Refurbished) |
| Coopervision INC. | $517.27 | 2019-2025 | Misight Contact Lens, Myday Contact Lens, Paragon Crt |
| Alcon Vision LLC | $400.78 | 2019-2025 | Clareon, Dailies Total1, Precision7 |
| Sun Pharmaceutical Industries INC. | $345.40 | 2019-2025 | Cequa |
| Johnson & Johnson Vision Care, INC. | $283.26 | 2019-2025 | Acuvue |
| Aerie Pharmaceuticals, INC. | $215.46 | 2019-2021 | |
| Oyster Point Pharma, INC. | $195.17 | 2022-2023 | Tyrvaya |
| Allergan, INC. | $175.81 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $174.99 | 2023-2024 | Miebo, Xiidra, Biotrue One Day |
| Novartis Pharmaceuticals Corporation | $136.88 | 2019-2021 | |
| Dompe US, INC. | $126.77 | 2021-2024 | Oxervate |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $101.20 | 2019-2020 | |
| Abbvie INC. | $61.83 | 2022-2023 | |
| Abb Con-Cise Optical Group LLC | $40.48 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $33.27 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $24.65 | 2019 | |
| Amgen INC. | $22.83 | 2025 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Koh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.